Literature DB >> 18787907

Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs.

Robert A Yood1, Kathleen M Mazor, Susan E Andrade, Srinivas Emani, Wing Chan, Kristijan H Kahler.   

Abstract

BACKGROUND: There are effective treatments to prevent osteoporotic fractures, but these treatments are underutilized.
OBJECTIVE: To evaluate the influence of patient characteristics, perceptions, knowledge and beliefs about osteoporosis on the decision to initiate osteoporotic treatment. PARTICIPANTS: We identified female members of a managed care plan who had a dual energy x-ray absorptiometry (DXA) bone density test and fulfilled World Health Organization criteria for osteoporosis. Patients were excluded if they received osteoporotic medications in the prior 6 months. MEASUREMENTS: Patients were sent a questionnaire that included items assessing satisfaction with physician-patient communication, trust in the physician, osteoporosis knowledge and beliefs, beliefs about prescription medications, and perceptions of barriers to medication use. Administrative electronic health records were used to identify prescription drug use and health care utilization.
RESULTS: Two hundred and thirty-six women returned surveys and research authorization forms out of 465 contacted for participation. One hundred and thirty-five (57.2%) filled a prescription for an osteoporotic drug in the first 3 months after the DXA exam. The largest differences between initiators and non-initiators were in beliefs in the benefits of medications, and distrust of medications, with initiators believing more strongly in the benefits and effectiveness of medications (p < .001), and non-initiators reporting more distrust of medications (p < .001). Osteoporosis knowledge and the belief that osteoporosis is a serious disease were also related to therapy initiation in bivariate analysis.
CONCLUSIONS: Only 57% of patients initiated osteoporotic medication within 3 months of diagnosis. The decision to start osteoporosis treatment appeared to be related to a patient's beliefs in the effectiveness of osteoporosis medications and distrust of medications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787907      PMCID: PMC2585659          DOI: 10.1007/s11606-008-0772-0

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  34 in total

1.  Meta-analysis of trials of interventions to improve medication adherence.

Authors:  Andrew M Peterson; Liza Takiya; Rebecca Finley
Journal:  Am J Health Syst Pharm       Date:  2003-04-01       Impact factor: 2.637

Review 2.  The Medication Adherence Model: a guide for assessing medication taking.

Authors:  Mary Jayne Johnson
Journal:  Res Theory Nurs Pract       Date:  2002       Impact factor: 0.688

3.  Reasons for adherence with antihypertensive medication.

Authors:  S Svensson; K I Kjellgren; J Ahlner; R Säljö
Journal:  Int J Cardiol       Date:  2000 Nov-Dec       Impact factor: 4.164

4.  Patients' decisions about whether or not to take antihypertensive drugs: qualitative study.

Authors:  John Benson; Nicky Britten
Journal:  BMJ       Date:  2002-10-19

5.  Compliance of osteoporotic patients with different treatment regimens.

Authors:  Elena Segal; Ada Tamir; Sophia Ish-Shalom
Journal:  Isr Med Assoc J       Date:  2003-12       Impact factor: 0.892

6.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

7.  Compliance with drug therapies for the treatment and prevention of osteoporosis.

Authors:  Jeffrey S McCombs; Patrick Thiebaud; Connie McLaughlin-Miley; Jinhai Shi
Journal:  Maturitas       Date:  2004-07-15       Impact factor: 4.342

8.  Early discontinuation of treatment for osteoporosis.

Authors:  Anna N A Tosteson; Margaret R Grove; Cristina S Hammond; Megan M Moncur; G Thomas Ray; Gwen M Hebert; Alice R Pressman; Bruce Ettinger
Journal:  Am J Med       Date:  2003-08-15       Impact factor: 4.965

9.  Consequences of poor compliance with bisphosphonates.

Authors:  Becky A Briesacher; Susan E Andrade; Robert A Yood; Kristijan H Kahler
Journal:  Bone       Date:  2007-07-18       Impact factor: 4.398

10.  Nonadherence and osteoporosis treatment preferences of older women: a qualitative study.

Authors:  C G Unson; E Siccion; J Gaztambide; S Gaztambide; P Mahoney Trella; K Prestwood
Journal:  J Womens Health (Larchmt)       Date:  2003-12       Impact factor: 2.681

View more
  43 in total

1.  Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors.

Authors:  F Douglas; K J Petrie; T Cundy; A Horne; G Gamble; A Grey
Journal:  Osteoporos Int       Date:  2011-11-08       Impact factor: 4.507

2.  Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule.

Authors:  D H Solomon; M A Brookhart; P Tsao; D Sundaresan; S E Andrade; K Mazor; R Yood
Journal:  Osteoporos Int       Date:  2010-09-29       Impact factor: 4.507

3.  Interventions aimed at improving performance on medication adherence metrics.

Authors:  Brandy McGinnis; Yardlee Kauffman; Kari L Olson; Daniel M Witt; Marsha A Raebel
Journal:  Int J Clin Pharm       Date:  2014-02

4.  Use of a performance algorithm improves utilization of vertebral fracture assessment in clinical practice.

Authors:  J T Schousboe; F McKiernan; J T Fuehrer; N Binkley
Journal:  Osteoporos Int       Date:  2014-03       Impact factor: 4.507

5.  The theory of planned behaviour explains intentions to use antiresorptive medication after a fragility fracture.

Authors:  Joanna E M Sale; Cathy Cameron; Stephen Thielke; Lynn Meadows; Kevin Senior
Journal:  Rheumatol Int       Date:  2017-04-18       Impact factor: 2.631

6.  Self-perception of fracture risk: what can it tell us?

Authors:  A E Litwic; J E Compston; A Wyman; E S Siris; S H Gehlbach; J D Adachi; R Chapurlat; A Díez-Pérez; A Z LaCroix; J W Nieves; J C Netelenbos; J Pfeilschifter; M Rossini; C Roux; K G Saag; S Silverman; N B Watts; S L Greenspan; L March; C L Gregson; C Cooper; E M Dennison
Journal:  Osteoporos Int       Date:  2017-08-31       Impact factor: 4.507

7.  Learning from marketing: Rapid development of medication messages that engage patients.

Authors:  Veronica Yank; Erika Tribett; Lydia Green; Jasmine Pettis
Journal:  Patient Educ Couns       Date:  2015-03-14

8.  Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials.

Authors:  S R Majumdar; F A McAlister; J A Johnson; D L Weir; D Bellerose; D A Hanley; A S Russell; B H Rowe
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

9.  Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial.

Authors:  Maria I Danila; Ryan C Outman; Elizabeth J Rahn; Amy S Mudano; David T Redden; Peng Li; Jeroan J Allison; Fred A Anderson; Allison Wyman; Susan L Greenspan; Andrea Z LaCroix; Jeri W Nieves; Stuart L Silverman; Ethel S Siris; Nelson B Watts; Michael J Miller; Jeffrey R Curtis; Amy H Warriner; Nicole C Wright; Kenneth G Saag
Journal:  J Bone Miner Res       Date:  2018-02-26       Impact factor: 6.741

10.  Determinant factors of osteoporosis patients' reported therapeutic adherence to calcium and/or vitamin D supplements: a cross-sectional, observational study of postmenopausal women.

Authors:  José Sanfelix-Genovés; Vicente F Gil-Guillén; Domingo Orozco-Beltran; Vicente Giner-Ruiz; Salvador Pertusa-Martínez; Begoña Reig-Moya; Concepción Carratalá
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.